Establishment Labs (NASDAQ:ESTA) Given New $71.00 Price Target at JPMorgan Chase & Co.

Establishment Labs (NASDAQ:ESTA) had its price target hoisted by JPMorgan Chase & Co. from $45.00 to $71.00 in a report issued on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research analysts have also commented on the stock. BTIG Research raised their price objective on shares of Establishment Labs from $62.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research report on Tuesday, October 7th. Wall Street Zen raised Establishment Labs from a “sell” rating to a “hold” rating in a research note on Sunday, October 19th. Mizuho boosted their price target on shares of Establishment Labs from $70.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Needham & Company LLC raised their price objective on shares of Establishment Labs from $48.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $66.71.

Establishment Labs Stock Performance

ESTA traded up $0.09 during trading hours on Thursday, hitting $65.00. The company’s stock had a trading volume of 1,048,731 shares, compared to its average volume of 495,430. The company has a 50-day simple moving average of $44.13 and a 200 day simple moving average of $40.41. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 9.71. The firm has a market capitalization of $1.88 billion, a PE ratio of -22.89 and a beta of 0.98. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $65.45.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.16. The business had revenue of $53.78 million during the quarter, compared to the consensus estimate of $52.28 million. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 201.85%. The company’s quarterly revenue was up 33.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.59) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Establishment Labs will post -2.41 EPS for the current year.

Institutional Investors Weigh In On Establishment Labs

A number of large investors have recently made changes to their positions in ESTA. State of Wyoming purchased a new stake in shares of Establishment Labs in the 3rd quarter valued at approximately $71,000. ANTIPODES PARTNERS Ltd acquired a new stake in Establishment Labs during the 1st quarter valued at $81,000. Osaic Holdings Inc. lifted its holdings in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares in the last quarter. CWM LLC boosted its position in shares of Establishment Labs by 45.9% in the second quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after buying an additional 686 shares during the period. Finally, Brian Low Financial Group LLC acquired a new stake in shares of Establishment Labs in the third quarter worth $223,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.